	US 12,083,157 B2
	Use of polylysine dendrimers in the prevention and management of acne-prone skin and acneic skin
Joan Attia-Vigneau, Saint Clar De Riviere (FR); Estelle Loing, Quebec (CA); and Magali Borel, Paris (FR)
Assigned to LUCAS MEYER COSMETICS, Massy (FR)
Appl. No. 17/441,482
Filed by Lucas Meyer Cosmetics, Massy (FR)
PCT Filed Feb. 21, 2020, PCT No. PCT/US2020/019173 § 371(c)(1), (2) Date Sep. 21, 2021, PCT Pub. No. WO2020/197669, PCT Pub. Date Oct. 1, 2020.
Claims priority of provisional application 62/823,730, filed on Mar. 26, 2019.
Prior Publication US 2022/0152147 A1, May 19, 2022
Int. Cl. A61K 38/16 (2006.01); A61K 8/362 (2006.01); A61K 8/365 (2006.01); A61K 8/64 (2006.01); A61K 8/67 (2006.01); A61P 17/10 (2006.01); A61Q 17/00 (2006.01); A61Q 19/00 (2006.01)

CPC A61K 38/16 (2013.01) [A61K 8/362 (2013.01); A61K 8/365 (2013.01); A61K 8/64 (2013.01); A61K 8/671 (2013.01); A61P 17/10 (2018.01); A61Q 17/005 (2013.01); A61K 2800/5426 (2013.01); A61K 2800/544 (2013.01)]

14 Claims

1. A method for managing a skin type selected from acneic skin, acne-prone skin and blemish-prone skin in a subject which comprises a step of topically administering an effective amount of a topical composition comprising an excipient and polylysine dendrimer or a salt thereof to said subject, wherein the polylysine dendrimer is an unconjugated poly-L-lysine second generation (G2) dendrigraft having an average degree of polymerization (DPn) from 40 to 60.